RxDoctor Payments Data

Amie Rainey, NP

Family · Pikeville, TNNPI 1093016081

Payments from drug & device makers

$1,185in general payments, 2019–2025

Across 70 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$525
  • AstraZeneca$186
  • Otsuka America Pharmaceutical, Inc.$186
  • Lilly USA, LLC$55
  • Axsome Therapeutics, Inc.$52
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$46
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$1,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,185 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$472
Medicare patients
11
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$150,336
MounjaroTirzepatide94$109,643
FarxigaDapagliflozin Propanediol97$83,277
Dupixent SyringeDupilumab13$48,453
JardianceEmpagliflozin41$33,937
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$33,778
UbrelvyUbrogepant22$31,290
EliquisApixaban50$31,133
VraylarCariprazine Hcl16$25,567
LinzessLinaclotide33$24,515
KerendiaFinerenone24$21,035
Buprenorphine44$15,658
Tresiba Flextouch U-200Insulin Degludec16$13,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,133
TrintellixVortioxetine Hydrobromide22$12,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$150,336146 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$186$120,260152 claims
Lilly USA, LLCMounjaro$55$109,64394 claims
AbbVieUbrelvy, Vraylar, Linzess$525$81,37271 claims
BayerKerendia$15$21,03524 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$12$12,94922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Pikeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →